骨靶向放射性核素治疗转移性去势抵抗性前列腺癌骨转移的总体生存:随机临床试验个体患者数据荟萃分析
该研究基于6项随机临床试验共2081例转移性去势抵抗性前列腺癌(CRPC)骨转移患者,比较骨靶向放射性核素(RI)与无RI的总体生存(OS)。
要点
- 骨靶向RI与CRPC骨转移患者OS的关联在固定效应模型下显著,随机效应模型下不显著。
核心结论
- 在转移性CRPC中,骨靶向α发射体RI而非β发射体RI可显著改善OS和无症状性骨骼事件(SSE)生存。
- 鉴于试验间异质性,结果外推需谨慎。
研究设计与样本
- 研究为个体患者数据荟萃分析,检索1993年1月至2013年6月PubMed、Cochrane Library、ClinicalTrials.gov及会议记录。
- 纳入6项随机临床试验共2081例经组织学证实的前列腺癌、去势后进展且有骨转移证据的患者。
关键数值与推荐
- 纳入试验需比较RI与无RI(安慰剂、外照射或化疗),且为随机设计,招募超过50例患者。
- 9项随机临床试验符合条件,3项因数据不足被排除。
临床怎么用
- 对于转移性CRPC骨转移患者,骨靶向α发射体镭-223可考虑用于改善OS和SSE生存。
- 使用RI时需注意血液学毒性风险增加。
局限性
- 试验间存在高度异质性(I2=80%),随机效应模型下OS关联不显著。
- 结果外推需谨慎,部分归因于离群试验和RI类型差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Both α-emitting and β-emitting bone-targeted radioisotopes (RIs) have been developed to treat men with metastatic castration-resistant prostate cancer (CRPC). Only 1 phase 3 randomized clinical trial has demonstrated an overall survival (OS) benefit from an α-emitting RI, radium 223 (223Ra), vs standard of care. Yet no head-to-head comparison has been done between α-emitting and β-emitting RIs. OBJECTIVE: To assess OS in men with bone metastases from CRPC treated with bone-targeted RIs and to compare the effects of α-emitting RIs with β-emitting RIs. DATA SOURCES: PubMed, Cochrane Library, ClinicalTrials.gov, and meeting proceedings between January 1993 and June 2013 were reviewed. Key terms included randomized trials, radioisotopes, radiopharmaceuticals, and prostate cancer. Data were collected, checked, and analyzed from February 2017 to October 2018. STUDY SELECTION: Selected trials included patients with prostate cancer, recruited more than 50 patients from January 1993 to June 2013, compared RI use with no RI use (placebo, external radiotherapy, or chemotherapy), and were randomized. Patients were diagnosed with histologically proven prostate cancer and disease progression after both surgical or chemical castration and have evidence of bone metastasis. Nine randomized clinical trials were identified as eligible, but 3 were excluded for insufficient data. DATA EXTRACTION AND SYNTHESIS: Individual patient data were requested for each eligible trial, and all data were checked with a standard procedure. The log-rank test stratified by trial was used to estimate hazard ratios (HRs), and a similar fixed-effects (FE) model was used to estimate odds ratios (ORs). The between-trial heterogeneity of treatment effects was evaluated by Cochran test and I2 and was accounted by a random-effects (RE) model. MAIN OUTCOMES AND MEASURES: Overall survival; secondary outcomes were symptomatic skeletal event (SSE)-free survival and adverse events. RESULTS: Based on 6 randomized clinical trials including 2081 patients, RI use was significantly associated with OS compared with no RI use (HR, 0.86; 95% CI, 0.77-0.95; P = .004) with high heterogeneity (χ25 = 24.46; P < .001; I2 = 80%), but this association disappeared when using an RE model (HR, 0.80; 95% CI, 0.61-1.06; P = .12; τ2 = 0.08). The heterogeneity is explained both by the type of RI and by the inclusion of 2 outlier trials that included 275 patients; the OS benefit was significantly higher with the α-emitting RI 223Ra (HR, 0.70; 95% CI, 0.58-0.83) but not significant with the β-emitting RI strontium-89 (HR, 0.96; 95% CI, 0.84-1.10) (P for interaction = .004). Excluding the outlier trials led to an overall HR of 0.82 (95% CI, 0.73-0.92; P < .001) (between-trial heterogeneity: χ23 = 6.51; P = .09; I2 = 54%) using an FE model and an HR of 0.80 (95% CI, 0.65-0.99; P = .04; τ2 = 0.02) using an RE model. The HR for SSE-free survival was 0.81 (95% CI, 0.69-0.93; P = .004) (between-trial heterogeneity: χ23 = 6.71; P = .08; I2 = 55%) when using an FE model and was 0.76 (95% CI, 0.58-1.01; P = .06; τ2 = 0.04) when using an RE model. There were more hematological toxic effects with RI use compared with no RI use (OR, 1.48; 95% CI, 1.17-1.88; P = .001). CONCLUSIONS AND RELEVANCE: In metastatic CRPC, a significant improvement of OS and SSE-free survival was obtained with bone-targeted α-emitting but not β-emitting RIs. Caution is necessary for generalizability of these results, given the between-trial heterogeneity.
引用
- Terrisse S, Karamouza E, Parker CC, et al. Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials. JAMA Oncol. 2020. PMID: 31830233. doi:10.1001/jamaoncol.2019.4097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。